跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 635 条关于
“ImmuneOnco Biopharmaceuticals”
全部
635
临床试验
5
药物
184
机构
97
资讯
349
去年
Instil Bio and ImmuneOnco Advance PD-(L)1xVEGF Bispecific Antibody Clinical Development Strategy
去年
ImmuneOnco's IMM27M Shows Promise in Phase I Breast Cancer Trial, Advancing to Phase II
去年
Instil Bio's Partner ImmuneOnco Doses First Patient in NSCLC Trial with IMM2510/SYN-2510
去年
ImmuneOnco's CD47xCD20 Bispecific IMM0306 Advances to Phase II with Promising Efficacy in B-Cell Lymphomas
8个月前
Instil Bio Terminates Licensing Agreement and Discontinues Lead Cancer Drug Development
去年
Jefferies Upgrades Instil Bio, Highlighting Potential of SYN2510 in Cancer Treatment
去年
Provectus Biopharmaceuticals Launches VisiRose for Ophthalmic Therapies
去年
Angitia Biopharmaceuticals Doses First Patient in Phase 2 Trial of AGA2118 for Osteoporosis
9个月前
SK Biopharmaceuticals' Cenobamate and Solriamfetol Receive NMPA Approval for China Market
9个月前
SK Biopharmaceuticals Licenses WT-7695 Radiopharmaceutical Targeting CA9 for Solid Tumors
第 1 页，共 35 页
上一页
下一页
